Cite
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
MLA
Abbasi, Ahmed, et al. “Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients with Refractory Large B Cell Lymphoma Including Two with HIV and Viral Hepatitis.” Journal of Hematology & Oncology, vol. 13, no. 1, Jan. 2020, pp. 1–4. EBSCOhost, https://doi.org/10.1186/s13045-019-0838-y.
APA
Abbasi, A., Peeke, S., Shah, N., Mustafa, J., Khatun, F., Lombardo, A., Abreu, M., Elkind, R., Fehn, K., de Castro, A., Wang, Y., Derman, O., Nelson, R., Uehlinger, J., Gritsman, K., Sica, R. A., Kornblum, N., Mantzaris, I., Shastri, A., & Janakiram, M. (2020). Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. Journal of Hematology & Oncology, 13(1), 1–4. https://doi.org/10.1186/s13045-019-0838-y
Chicago
Abbasi, Ahmed, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, et al. 2020. “Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients with Refractory Large B Cell Lymphoma Including Two with HIV and Viral Hepatitis.” Journal of Hematology & Oncology 13 (1): 1–4. doi:10.1186/s13045-019-0838-y.